Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.
Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China; Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Clin Breast Cancer. 2021 Aug;21(4):360-372. doi: 10.1016/j.clbc.2021.02.012. Epub 2021 Mar 5.
Although patients diagnosed with ductal carcinoma in situ (DCIS) harbor excellent overall survival (OS) after breast-conserving therapy, the evidence regarding to surgical management for ipsilateral breast tumor recurrence (IBTR) is scarce. This study aimed to assess the prognosis of repeated breast-conserving surgery (BCS) versus mastectomy for IBTR in DCIS survivors.
Herein, 5344 DCIS cases with IBTR were identified during 702,748 person-years of follow-up, 3532 (66.09%) received mastectomy, and 1812 (33.91%) received repeated BCS. Cox regression and competing risk regression were employed to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for OS and breast cancer-specific survival (BCSS), which was respectively calculated within spontaneous and matched cohorts.
After adjustment for confounders, no statistically significant survival difference was observed between the repeated BCS and mastectomy for patients with DCIS with IBTR. The stratified analyses further revealed that patients with DCIS with IBTR receiving repeated BCS combined with radiation therapy were associated with both superior OS (HR, 0.79; CI, 0.64-0.98; P = .04) and BCSS (HR, 0.54; CI, 0.33-0.90; P = .02) compared with counterparts undergoing mastectomy. Furthermore, patients with DCIS who were age older than 60 years at IBTR diagnosis benefit from repeated BCS with radiotherapy (HR, 0.44; CI, 0.24-0.84; P = .01) than mastectomy.
We suggest that repeated BCS with radiation therapy deserves consideration when DCIS survivors suffered IBTR. The choice of surgical management should be tailored based on patients' age at IBTR diagnosis and size of recurrent disease.
尽管接受保乳治疗的导管原位癌(DCIS)患者总体生存(OS)良好,但关于同侧乳房肿瘤复发(IBTR)的手术管理证据有限。本研究旨在评估 IBTR 中 DCIS 幸存者重复保乳手术(BCS)与乳房切除术的预后。
在此,在 702748 人年的随访中,共确定了 5344 例 DCIS 伴 IBTR 病例,其中 3532 例(66.09%)接受乳房切除术,1812 例(33.91%)接受重复 BCS。采用 Cox 回归和竞争风险回归估计多变量调整后的 OS 和乳腺癌特异性生存(BCSS)的风险比(HR)和 95%置信区间(CI),并分别在自发和匹配队列中计算。
调整混杂因素后,IBTR 中 DCIS 患者重复 BCS 与乳房切除术之间的生存差异无统计学意义。分层分析进一步表明,IBTR 中 DCIS 患者接受重复 BCS 联合放疗的 OS(HR,0.79;CI,0.64-0.98;P=0.04)和 BCSS(HR,0.54;CI,0.33-0.90;P=0.02)均优于接受乳房切除术的患者。此外,IBTR 诊断时年龄大于 60 岁的 DCIS 患者接受放疗的重复 BCS(HR,0.44;CI,0.24-0.84;P=0.01)优于乳房切除术。
我们建议,当 DCIS 幸存者发生 IBTR 时,应考虑重复 BCS 联合放疗。手术管理的选择应根据患者 IBTR 时的年龄和复发病灶的大小来定制。